

Elizabeth A Ashley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6042221/publications.pdf>

Version: 2024-02-01

144
papers

14,808
citations

71004

43
h-index

25983

112
g-index

149
all docs

149
docs citations

149
times ranked

10322
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of vivax malaria: A collection review. PLoS Medicine, 2022, 19, e1003890.	3.9	25
2	Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, The, 2022, 399, 629-655.	6.3	4,915
3	A case-control study of the causes of acute respiratory infection among hospitalized patients in Northeastern Laos. Scientific Reports, 2022, 12, 939.	1.6	5
4	Have we really failed to roll back malaria?. Lancet, The, 2022, 399, 799-800.	6.3	14
5	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	2.0	33
6	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	1.8	1
7	Nitrofurantoin and glucose-6-phosphate dehydrogenase deficiency: a safety review. JAC-Antimicrobial Resistance, 2022, 4, dlac045.	0.9	3
8	STARTER Checklist for Antimalarial Therapeutic Efficacy Reporting. American Journal of Tropical Medicine and Hygiene, 2022, 107, 1-3.	0.6	1
9	Antimicrobial resistance patterns in bacteria causing febrile illness in Africa, South Asia, and Southeast Asia: a systematic review of published etiological studies from 1980-2015. International Journal of Infectious Diseases, 2022, 122, 612-621.	1.5	6
10	Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment. Trends in Parasitology, 2022, 38, 711-718.	1.5	1
11	Evaluation of trends in hospital antimicrobial use in the Lao PDR using repeated point-prevalence surveys-evidence to improve treatment guideline use. The Lancet Regional Health - Western Pacific, 2022, 27, 100531.	1.3	4
12	Prediction of disease severity in young children presenting with acute febrile illness in resource-limited settings: a protocol for a prospective observational study. BMJ Open, 2021, 11, e045826.	0.8	12
13	Inter-prescriber variability in the decision to prescribe antibiotics to febrile patients attending primary care in Myanmar. JAC-Antimicrobial Resistance, 2021, 3, dlaa118.	0.9	2
14	Serological evidence indicates widespread distribution of rickettsioses in Myanmar. International Journal of Infectious Diseases, 2021, 103, 494-501.	1.5	5
15	Impact of delays to incubation and storage temperature on blood culture results: a multi-centre study. BMC Infectious Diseases, 2021, 21, 173.	1.3	13
16	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	0.9	97
17	Observational study of adult respiratory infections in primary care clinics in Myanmar: understanding the burden of melioidosis, tuberculosis and other infections not covered by empirical treatment regimes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 914-921.	0.7	4
18	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 2021, 6, 64.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Geographical distribution of <i>Burkholderia pseudomallei</i> in soil in Myanmar. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009372.	1.3	7
20	Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant <i>falciparum</i> malaria: a cluster-randomised trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1579-1589.	4.6	8
21	Surveillance strategies using routine microbiology for antimicrobial resistance in low- and middle-income countries. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1391-1399.	2.8	20
22	Laboratory informatics capacity for effective antimicrobial resistance surveillance in resource-limited settings. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e170-e174.	4.6	13
23	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	0.9	51
24	Dengue diagnostic test use to identify <i>Aedes</i> -borne disease hotspots. <i>Lancet Planetary Health</i> , The, 2021, 5, e503.	5.1	1
25	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. <i>ELife</i> , 2021, 10, .	2.8	53
26	The 20-minute whole blood clotting test (20WBCT) for snakebite coagulopathy—A systematic review and meta-analysis of diagnostic test accuracy. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009657.	1.3	22
27	The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003766.	3.9	4
28	Evolution of Multidrug Resistance in <i>Plasmodium falciparum</i> : a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0112121.	1.4	21
29	Enhanced melioidosis surveillance in patients attending four tertiary hospitals in Yangon, Myanmar. <i>Epidemiology and Infection</i> , 2021, 149, 1-23.	1.0	2
30	High burden of infections caused by ESBL-producing MDR <i>Escherichia coli</i> in paediatric patients, Yangon, Myanmar. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab011.	0.9	3
31	Antimicrobial resistance detection in Southeast Asian hospitals is critically important from both patient and societal perspectives, but what is its cost?. <i>PLOS Global Public Health</i> , 2021, 1, e0000018.	0.5	6
32	Antimicrobial use and resistance data in human and animal sectors in the Lao PDR: evidence to inform policy. <i>BMJ Global Health</i> , 2021, 6, e007009.	2.0	11
33	Epidemiology of Extended-Spectrum Beta-Lactamase and Carbapenemase-Producing Enterobacterales in the Greater Mekong Subregion: A Systematic-Review and Meta-Analysis of Risk Factors Associated With Extended-Spectrum Beta-Lactamase and Carbapenemase Isolation. <i>Frontiers in Microbiology</i> , 2021, 12, 695027.	1.5	7
34	Antimicrobial resistance in commensal opportunistic pathogens isolated from non-sterile sites can be an effective proxy for surveillance in bloodstream infections. <i>Scientific Reports</i> , 2021, 11, 23359.	1.6	2
35	Utility of InTray COLOREX Screen agar and InTray COLOREX ESBL agar for urine culture in the Lao PDR. <i>JAC-Antimicrobial Resistance</i> , 2021, 4, dlac006.	0.9	0
36	Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Africa, 1980–2015. <i>BMC Medicine</i> , 2020, 18, 279.	2.3	31

#	ARTICLE	IF	CITATIONS
37	Myanmar <i>Burkholderia pseudomallei</i> strains are genetically diverse and originate from Asia with phylogenetic evidence of reintroductions from neighbouring countries. <i>Scientific Reports</i> , 2020, 10, 16260.	1.6	11
38	Seasonal malaria chemoprevention: closing the know- <i>do</i> gap. <i>Lancet</i> , The, 2020, 396, 1778-1779.	6.3	9
39	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1470-1480.	4.6	94
40	Case-based surveillance of antimicrobial resistance in the ACORN (A Clinically Oriented Antimicrobial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.9	4
41	Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Southern Asia and South-eastern Asia, 1980-2015. <i>BMC Medicine</i> , 2020, 18, 299.	2.3	30
42	Treatment and prevention of malaria in children. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 775-789.	2.7	34
43	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 943-952.	4.6	25
44	Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. <i>BMC Medicine</i> , 2020, 18, 138.	2.3	16
45	Setting priorities for patient-centered surveillance of drug-resistant infections. <i>International Journal of Infectious Diseases</i> , 2020, 97, 60-65.	1.5	4
46	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial. <i>Lancet</i> , The, 2020, 395, 1345-1360.	6.3	182
47	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. <i>PLoS Medicine</i> , 2020, 17, e1003040.	3.9	20
48	Evaluation of the forum theatre approach for public engagement around antibiotic use in Myanmar. <i>PLoS ONE</i> , 2020, 15, e0235625.	1.1	14
49	<i>Plasmodium falciparum</i> ATP4 inhibitors to treat malaria: worthy successors to artemisinin?. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 883-885.	4.6	2
50	ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance. <i>Wellcome Open Research</i> , 2020, 5, 13.	0.9	18
51	A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices. <i>PLoS Genetics</i> , 2020, 16, e1009037.	1.5	5
52	The risk of <i>Plasmodium vivax</i> parasitaemia after <i>P. falciparum</i> malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. <i>PLoS Medicine</i> , 2020, 17, e1003393.	3.9	32
53	A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008109.	1.3	4
54	Automating the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in Seven Countries. <i>Journal of Medical Internet Research</i> , 2020, 22, e19762.	2.1	14

#	ARTICLE	IF	CITATIONS
55	ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance. Wellcome Open Research, 2020, 5, 13.	0.9	13
56	Title is missing!. , 2020, 16, e1009037.		0
57	Title is missing!. , 2020, 16, e1009037.		0
58	Title is missing!. , 2020, 16, e1009037.		0
59	Title is missing!. , 2020, 16, e1009037.		0
60	Title is missing!. , 2020, 17, e1003393.		0
61	Title is missing!. , 2020, 17, e1003393.		0
62	Title is missing!. , 2020, 17, e1003393.		0
63	Title is missing!. , 2020, 17, e1003393.		0
64	Title is missing!. , 2020, 17, e1003393.		0
65	Title is missing!. , 2020, 14, e0008109.		0
66	Title is missing!. , 2020, 14, e0008109.		0
67	Title is missing!. , 2020, 14, e0008109.		0
68	Title is missing!. , 2020, 14, e0008109.		0
69	Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases, The, 2019, 19, 952-961.	4.6	252
70	The effect of dose on the antimalarial efficacy of artesunate-mefloquine against Plasmodium falciparum malaria: a protocol for systematic review and individual patient data (IPD) meta-analysis. BMJ Open, 2019, 9, e027738.	0.8	4
71	Standardising the reporting of microbiology and antimicrobial susceptibility data. Lancet Infectious Diseases, The, 2019, 19, 1163-1164.	4.6	8
72	Defining System Requirements for Simplified Blood Culture to Enable Widespread Use in Resource-Limited Settings. Diagnostics, 2019, 9, 10.	1.3	29

#	ARTICLE	IF	CITATIONS
73	Harnessing alternative sources of antimicrobial resistance data to support surveillance in low-resource settings. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 541-546.	1.3	18
74	<i>Plasmodium vivax</i> Relapse Rates Following <i>Plasmodium falciparum</i> Malaria Reflect Previous Transmission Intensity. <i>Journal of Infectious Diseases</i> , 2019, 220, 100-104.	1.9	19
75	Presence of <i>Burkholderia pseudomallei</i> in the “Granary of Myanmar”™. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 8.	0.9	5
76	Genomic structure and diversity of <i>Plasmodium falciparum</i> in Southeast Asia reveal recent parasite migration patterns. <i>Nature Communications</i> , 2019, 10, 2665.	5.8	46
77	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. <i>Journal of Infectious Diseases</i> , 2019, 220, 1178-1187.	1.9	21
78	Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. <i>BMC Medicine</i> , 2019, 17, 70.	2.3	55
79	An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1737-1749.	1.3	47
80	Malaria. <i>Lancet</i> , The, 2018, 391, 1608-1621.	6.3	374
81	Malaria elimination in remote communities requires integration of malaria control activities into general health care: an observational study and interrupted time series analysis in Myanmar. <i>BMC Medicine</i> , 2018, 16, 183.	2.3	40
82	Drugs in Development for Malaria. <i>Drugs</i> , 2018, 78, 861-879.	4.9	154
83	Grading antimicrobial susceptibility data quality: room for improvement. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 603-604.	4.6	12
84	Melioidosis in Myanmar. <i>Tropical Medicine and Infectious Disease</i> , 2018, 3, 28.	0.9	12
85	Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006230.	1.3	120
86	Poor response to artesunate treatment in two patients with severe malaria on the Thai-Myanmar border. <i>Malaria Journal</i> , 2018, 17, 30.	0.8	16
87	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002579.	3.9	47
88	Measuring Mosquito-borne Viral Suitability in Myanmar and Implications for Local Zika Virus Transmission. <i>PLOS Currents</i> , 2018, 10, .	1.4	10
89	Artemisinin resistance without pfcy10 mutations in <i>Plasmodium falciparum</i> isolates from Cambodia. <i>Malaria Journal</i> , 2017, 16, 195.	0.8	99
90	Longitudinal genomic surveillance of <i>Plasmodium falciparum</i> malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. <i>Genome Biology</i> , 2017, 18, 78.	3.8	120

#	ARTICLE	IF	CITATIONS
91	Investment in antimalarial drug development is bearing fruit. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 568-570.	4.6	2
92	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3515-3520.	3.3	78
93	Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites. <i>Molecular Biology and Evolution</i> , 2017, 34, 131-144.	3.5	87
94	Post-malaria neurological syndromes. <i>Clinical Medicine</i> , 2017, 17, 95.	0.8	0
95	A current perspective on antimicrobial resistance in Southeast Asia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2963-2972.	1.3	139
96	Antimicrobial resistance in Africa: a systematic review. <i>BMC Infectious Diseases</i> , 2017, 17, 616.	1.3	310
97	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. <i>PLoS Medicine</i> , 2017, 14, e1002212.	3.9	50
98	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. <i>Malaria Journal</i> , 2016, 15, 185.	0.8	43
99	Declining Efficacy of Artemisinin Combination Therapy Against <i>P. Falciparum</i> Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors. <i>Clinical Infectious Diseases</i> , 2016, 63, 784-791.	2.9	178
100	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant <i>Plasmodium falciparum</i> distributions in Southeast Asia. <i>International Journal of Health Geographics</i> , 2016, 15, 37.	1.2	13
101	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. <i>Malaria Journal</i> , 2015, 14, 359.	0.8	47
102	Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 505-513.	1.4	41
103	Genetic architecture of artemisinin-resistant <i>Plasmodium falciparum</i> . <i>Nature Genetics</i> , 2015, 47, 226-234.	9.4	515
104	Quality assurance of drugs used in clinical trials: proposal for adapting guidelines. <i>BMJ: British Medical Journal</i> , 2015, 350, h602.	2.4	17
105	Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach. <i>PLoS Medicine</i> , 2015, 12, e1001823.	3.9	36
106	Spread of artemisinin-resistant <i>Plasmodium falciparum</i> in Myanmar: a cross-sectional survey of the K13 molecular marker. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 415-421.	4.6	363
107	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. <i>BMC Medicine</i> , 2015, 13, 66.	2.3	37
108	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. <i>Science</i> , 2015, 347, 431-435.	6.0	362

#	ARTICLE	IF	CITATIONS
109	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. <i>New England Journal of Medicine</i> , 2014, 371, 411-423.	13.9	1,753
110	Primaquine: the risks and the benefits. <i>Malaria Journal</i> , 2014, 13, 418.	0.8	188
111	Pregnancy Outcome in Relation to Treatment of Murine Typhus and Scrub Typhus Infection: A Fever Cohort and a Case Series Analysis. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3327.	1.3	50
112	Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7340-7346.	1.4	42
113	Pharmacokinetic Interactions between Primaquine and Chloroquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3354-3359.	1.4	78
114	The duration of <i>Plasmodium falciparum</i> infections. <i>Malaria Journal</i> , 2014, 13, 500.	0.8	109
115	Participants' perceptions and understanding of a malaria clinical trial in Bangladesh. <i>Malaria Journal</i> , 2014, 13, 217.	0.8	14
116	Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria: two open-label, randomized trials in Nimba County, Liberia. <i>Malaria Journal</i> , 2013, 12, 250.	0.8	42
117	Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. <i>Malaria Journal</i> , 2013, 12, 251.	0.8	30
118	A Major Genome Region Underlying Artemisinin Resistance in Malaria. <i>Science</i> , 2012, 336, 79-82.	6.0	334
119	Antimicrobial susceptibility of bacterial isolates from community acquired infections in Sub-Saharan Africa and Asian low and middle income countries. <i>Tropical Medicine and International Health</i> , 2011, 16, 1167-1179.	1.0	67
120	<i>Plasmodium vivax</i> Recurrence Following <i>Falciparum</i> and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics. <i>Clinical Infectious Diseases</i> , 2011, 52, 612-620.	2.9	124
121	Arthropod Borne Disease: The Leading Cause of Fever in Pregnancy on the Thai-Burmese Border. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e888.	1.3	61
122	Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated <i>falciparum</i> malaria: an open-label randomised trial. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 673-681.	4.6	168
123	Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria: an open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 762-769.	4.6	96
124	Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated <i>Plasmodium falciparum</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3837-3846.	1.4	96
125	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. <i>PLoS ONE</i> , 2009, 4, e4551.	1.1	212
126	The relationship between the haemoglobin concentration and the haematocrit in <i>Plasmodium falciparum</i> malaria. <i>Malaria Journal</i> , 2008, 7, 149.	0.8	42

#	ARTICLE	IF	CITATIONS
127	How much fat is necessary to optimize lumefantrine oral bioavailability?. <i>Tropical Medicine and International Health</i> , 2007, 12, 195-200.	1.0	118
128	Pharmacokinetic study of artemether+lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. <i>Tropical Medicine and International Health</i> , 2007, 12, 201-208.	1.0	88
129	Electrocardiographic Safety Evaluation of Dihydroartemisinin+Piperaquine in the Treatment of Uncomplicated falciparum Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 447-450.	0.6	41
130	Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 447-50.	0.6	32
131	Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. <i>Lancet, The</i> , 2006, 367, 2075-2085.	6.3	133
132	An open label randomized comparison of mefloquine+artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. <i>Tropical Medicine and International Health</i> , 2006, 11, 1653-1660.	1.0	50
133	The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 1021-1031.	0.8	112
134	A Randomized, Controlled Study of a Simple, Once-Daily Regimen of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated, Multidrug-Resistant Falciparum Malaria. <i>Clinical Infectious Diseases</i> , 2005, 41, 425-432.	2.9	107
135	Randomized, Controlled Dose-Optimization Studies of Dihydroartemisinin+Piperaquine for the Treatment of Uncomplicated Multidrug-Resistant Falciparum Malaria in Thailand. <i>Journal of Infectious Diseases</i> , 2004, 190, 1773-1782.	1.9	104
136	Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. <i>Lancet, The</i> , 2004, 364, 438-447.	6.3	707
137	The utility of an AMR dictionary as an educational tool to improve public understanding of antimicrobial resistance. <i>Wellcome Open Research</i> , 0, 6, 113.	0.9	3
138	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. <i>Wellcome Open Research</i> , 0, 6, 216.	0.9	0
139	Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV). <i>Wellcome Open Research</i> , 0, 5, 241.	0.9	5
140	Climate change and health in Southeast Asia – defining research priorities and the role of the Wellcome Trust Africa Asia Programmes. <i>Wellcome Open Research</i> , 0, 6, 278.	0.9	2
141	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. <i>Wellcome Open Research</i> , 0, 6, 216.	0.9	1
142	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. <i>Wellcome Open Research</i> , 0, 6, 64.	0.9	11
143	An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. <i>Wellcome Open Research</i> , 0, 7, 136.	0.9	16
144	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	1